

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3811743/publications.pdf Version: 2024-02-01



DANIEL

#	Article	IF	CITATIONS
1	Estimating Survival in Patients With Lung Cancer and Brain Metastases. JAMA Oncology, 2017, 3, 827.	3.4	543
2	Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus–Associated Oropharynx Squamous Cell Carcinoma. Journal of Clinical Oncology, 2019, 37, 1909-1918.	0.8	150
3	A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro-Oncology, 2015, 17, 1261-1269.	0.6	126
4	Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma. Clinical Cancer Research, 2020, 26, 1094-1104.	3.2	124
5	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. Journal of the National Cancer Institute, 2021, 113, 742-751.	3.0	98
6	Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4506-4514.	1.8	86
7	Conditional probability of longâ€ŧerm survival in glioblastoma. Cancer, 2012, 118, 5608-5613.	2.0	79
8	Stereotactic body radiotherapy for primary hepatic malignancies – Report of a phase I/II institutional study. Radiotherapy and Oncology, 2016, 121, 79-85.	0.3	76
9	A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer. Thyroid, 2019, 29, 1615-1622.	2.4	51
10	Tumor volume discrepancies between FDG-PET and MRI for cervical cancer. Radiotherapy and Oncology, 2011, 98, 139-142.	0.3	42
11	Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier. Molecular Cancer Therapeutics, 2018, 17, 1893-1901.	1.9	37
12	Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer. Radiotherapy and Oncology, 2020, 147, 64-74.	0.3	34
13	Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review. Practical Radiation Oncology, 2016, 6, e117-e126.	1.1	26
14	Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. Journal of Pharmacology and Experimental Therapeutics, 2017, 363, 136-147.	1.3	25
15	VMAT Grid Therapy: A Widely Applicable Planning Approach. Practical Radiation Oncology, 2021, 11, e339-e347.	1.1	25
16	Oncologic outcomes of selective neck dissection in HPVâ€related oropharyngeal squamous cell carcinoma. Laryngoscope, 2017, 127, 623-630.	1.1	21
17	Implementation of Telehealth in Radiation Oncology: Rapid Integration During COVID-19 and Its Future Role in Our Practice. Advances in Radiation Oncology, 2021, 6, 100575.	0.6	20
18	Comparison of apparent diffusion coefficient maps to T2-weighted images for target delineation in cervix cancer brachytherapy. Journal of Contemporary Brachytherapy, 2011, 4, 193-198.	0.4	18

DANIEL

#	Article	IF	CITATIONS
19	Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. Journal of Pharmacology and Experimental Therapeutics, 2016, 356, 251-259.	1.3	18
20	Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294. Medical Physics, 2021, 48, e697-e732.	1.6	16
21	A Cervical Nerve Block Approach to Improve Safety. American Journal of Roentgenology, 2007, 189, 563-565.	1.0	13
22	Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones. Neuro-Oncology, 2020, 22, 70-83.	0.6	12
23	Mucosal Sparing Radiation Therapy in Resected Oropharyngeal Cancer. Annals of Otology, Rhinology and Laryngology, 2017, 126, 185-191.	0.6	9
24	Outcomes and patterns of failure of sarcomatoid carcinoma of the larynx: The Mayo Clinic experience. Laryngoscope, 2018, 128, 373-377.	1.1	9
25	Detectable HPV ctDNA in Post-Operative Oropharyngeal Squamous Cell Carcinoma Patients is Associated With Progression. International Journal of Radiation Oncology Biology Physics, 2019, 105, 682-683.	0.4	8
26	A Systematic Review on Re-irradiation with Charged Particle Beam Therapy in the Management of Locally Recurrent Skull Base and Head and Neck Tumors. International Journal of Particle Therapy, 2021, 8, 131-154.	0.9	8
27	Empowering Residents into Independent Practice: A Single-Institutional Endeavor Aimed at Developing Resident Autonomy Through Implementation of a Chief Resident Service in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2020, 107, 23-26.	0.4	6
28	Follow-Up and Management of Patients With Head and Neck Cancer During the 2019 Novel Coronavirus (SARS-CoV-2) Disease Pandemic. Advances in Radiation Oncology, 2020, 5, 631-636.	0.6	6
29	The Importance of Verification CT-QA Scans in Patients Treated with IMPT for Head and Neck Cancers. International Journal of Particle Therapy, 2020, 7, 41-53.	0.9	6
30	Positioning reproducibility with and without rotational corrections for 2 head and neck immobilization systems. Practical Radiation Oncology, 2015, 5, e575-e581.	1.1	5
31	Identifying the Most Costly Patients in Radiation Oncology and Predicting the Top Spenders. Journal of Oncology Practice, 2019, 15, e704-e716.	2.5	5
32	Disease Profile and Oncologic Outcomes After Delayed Diagnosis of Human Papillomavirus–Associated Oropharyngeal Cancer. Otolaryngology - Head and Neck Surgery, 2021, 165, 830-837.	1.1	4
33	Deintensification Strategies Using Proton Beam Therapy for HPV-Related Oropharyngeal Cancer. International Journal of Particle Therapy, 2021, 8, 223-233.	0.9	4
34	Treatment De-intensification for HPV-associated Oropharyngeal Cancer: A Definitive Surgery Paradigm. Seminars in Radiation Oncology, 2021, 31, 332-338.	1.0	4
35	Comparing the Survival, Recurrence, and Toxicities Between Surgery With Adjuvant Therapy Versus Surgery Alone for Human Papillomavirus–Positive Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2015, 93, S76.	0.4	2
36	Optimal Timing of Computed Tomography Verification Scans in Patients Treated With Spot-Scanning Intensity-Modulated Proton Therapy for Head and Neck Cancers. International Journal of Radiation Oncology Biology Physics, 2017, 99, E336-E337.	0.4	2

DANIEL

#	Article	IF	CITATIONS
37	Clinical Outcomes after Re-irradiation in Recurrent Head and Neck Cancers treated with Intensity Modulated Proton and Photon Therapies. International Journal of Radiation Oncology Biology Physics, 2019, 105, E382-E383.	0.4	2
38	Human Papillomavirus–Associated Anogenital Pathology in Females With HPV-Positive Oropharyngeal Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2021, 164, 369-374.	1.1	2
39	Initial Experience with Proton Beam Therapy for Differentiated Thyroid Cancer. International Journal of Particle Therapy, 2021, 8, 311-318.	0.9	2
40	Risk Factors for Locoregional Recurrence After Transoral Robotic Surgery for HPV+ Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, S122-S123.	0.4	1
41	In Reply to Garden. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1296-1297.	0.4	1
42	HPV16 L1 Capsid Antibody Titers and Prognosis in HPV Associated Malignancy: Oropharyngeal, Anal, Cervical and Vaginal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, E666.	0.4	1
43	Immunotherapy in Head and Neck Cancer—Ready for Prime Time or More Research Needed?. International Journal of Radiation Oncology Biology Physics, 2021, 109, 647-650.	0.4	1
44	Oncologic Outcomes for Head and Neck Skin Malignancies Treated with Protons. International Journal of Particle Therapy, 2021, 8, 294-303.	0.9	1
45	The role of total parotidectomy in high-grade parotid malignancy: A multisurgeon retrospective review. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2022, 43, 103194.	0.6	1
46	The Role of Functional Imaging in Radiotherapy Planning and Management for Gynecologic Malignancies. PET Clinics, 2011, 6, 195-205.	1.5	0
47	Risk of Delayed Lymph Node Metastasis in Cases of Esthesioneuroblastoma With a Clinically NO Neck. International Journal of Radiation Oncology Biology Physics, 2013, 87, S456-S457.	0.4	0
48	Dosimetric Effect of Intratreatment Target Volume Reduction in Bulky Head-and-Neck Cancer With Intensity Modulated Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, S742.	0.4	0
49	Role of Positron Emission Tomography and Computed Tomography Imaging for Detecting Disease Recurrence Following Adjuvant Radiation Therapy in Oropharyngeal Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 926.	0.4	0
50	The Impact of Total Laryngectomy on Non-oncologic Causes of Death in Patients Treated with Radiation Therapy for Advanced Larynx and Hypopharynx Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, S121.	0.4	0
51	Patient-reported Quality of Life during Photon and Proton Radiation Therapy: Results of a Prospective Registry of Patient Reported Outcomes in a Large-Volume, Multi-Site Practice. International Journal of Radiation Oncology Biology Physics, 2018, 102, e739.	0.4	0
52	An IMPT-IMRT Comparison of Acute Patient Reported Outcomes after Ipsilateral Radiation for Head and Neck Cancers. International Journal of Radiation Oncology Biology Physics, 2018, 102, S23-S24.	0.4	0
53	Something for Everyone From Low-Risk to High-Risk: 5 Recent Studies to Improve Treatment and Surveillance for All Patients With Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1-8.	0.4	0